華神科技(000790.SZ):子公司擬不超過4.8億元投建年產15000噸高端新材料和原料藥(含醫藥中間體) 綠色生產基地項目(一期)
格隆匯11月6日丨華神科技(000790.SZ)公佈,公司於2023年11月6日召開第十三屆董事會第六次會議,審議通過了《關於子公司投建15000噸/年高端新材料和原料藥(含醫藥中間體)綠色生產基地項目(一期)》(簡稱“項目”)的議案,同意在控股子公司山東凌凱藥業有限公司(簡稱“山東凌凱”)進行項目一期建設,項目一期計劃分階段建設,其中第一階段項目建設投資不超過4.8億元。
山東凌凱成立於2018年6月20日,是由公司全資子公司成都華神生物技術有限責任公司(簡稱“華神生物”)、上海凌凱醫藥科技有限公司(簡稱“凌凱醫藥”)共同出資成立。其中,華神生物佔山東凌凱總註冊資本的70%。山東凌凱依託其控股單位華神科技與凌凱醫藥在醫藥、新材料、綠色化工等高科技領域的擁有的產品及工藝技術研發優勢及品牌與資本平台優勢,充分結合現有控股單位面向國際化客户的技術、生產、營銷渠道平台資源,採用先進的連續流生產工藝,從事雙氟磺酰亞胺鋰、戊環嗎啉原料藥等精細化工產品或精細化工中間體(含原料藥、醫藥中間體)的生產銷售,建設年產約15000噸/年高端新材料和原料藥(含醫藥中間體)綠色生產基地項目。本項目主要建設一期系列產品,包括900噸/年戊環嗎啉原料藥合成的中間體、5000噸/年雙氟磺酰亞胺鋰(折固)、6000噸/年硫酰氟。其中第一階段包括1000噸/年雙氟磺酰亞胺鋰(折固)、1200噸/年硫酰氟,剩餘規劃產能及產品項目建設將視市場及本項目一期第一階段建設投運情況,在項目後續規劃期內統籌圍繞醫藥中間體、原料藥及製劑等領域產品開展有關規劃和實施工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.